spectrum® PHARMACY PRODUCTS

800.370.6231
SpectrumRx.com

SUGGESTED FORMULA

Chloramphenicol Palmitate 150mg/5mL Oral Suspension
Version number: 1.0
Volume or quantity: 100mL

Chloramphenicol Palmitate	5.22gm
Glycerin, NF (G1016)	XmL
Syrup, NF (SY105)	50mL
Methylcellulose 1% Solution	Q.S. 100mL

SUGGESTED COMPOUNDING PROCEDURES

Weigh all ingredients

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Using a mortar and pestle, triturate the Chloramphenicol palmitate to a fine powder
4. Add approximately 5mL of glycerin and mix to a uniform paste
5. Add syrup in approximately geometric portions, mixing thoroughly after each addition
6. Transfer the contents of the mortar to a previously calibrated bottle
7. Add methylcellulose 1% Solution, rinsing the mortar to bring the volume to 100mL
8. Shake Well package and label
9. Suggested Quality Assessments
    a. Solution is homogenous with no particulate
    b. Packaged in correct container
    c. Quantity – QS to final volume
    d. Label - auxiliary labels, storage, BUD, compounded medication

Store in air-tight container, at Controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.
It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date of 14 Days can be used for this preparation when stored in room temperature. Maximum stability at pH 6 but the drug is stable from pH 2 to 7. Decomposition is enhanced in the presence of heat and light.

Precautions:

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

5/18 JD